Results about: colorectal cancer

<p>Batlle</p>

Colorectal cancer (CRC) is the most frequent and the second-most deadly type of cancer with around 700,000 deaths worldwide.

IRB Barcelona paves the way to the use of immunotherapy to treat aggressive colon tumours and their metastasis

A team headed by ICREA researcher Eduard Batlle discovers that immune system-stimulating treatments combined with a TGF-beta inhibitor are effective against colon cancer.

The researchers developed a mouse model that mimics advanced human colon cancer. This model has allowed them to study the immune system response for the first time.

Olga Torres Foundation awards IRB Barcelona a grant to study immunotherapies for metastatic colorectal cancer

The project, headed by group leader and ICREA researcher Eduard Batlle, receives a 60,000-€ grant.

The study will test the effectiveness of immunotherapies to treat metastatic disease in advanced colorectal cancer.

Research will take place during the academic years 2017 and 2018.

 

A genome-editing strategy to study cancer stem cells in human tumours

In EMBO Molecular Medicine, IRB Barcelona scientists report a technique based on a combination of CRISPR/Cas9 genome editing and patient-derived tumour organoids that allows the study of cell heterogeneity in human tumours.

The novel approach was used to examine the behaviour of colorectal cancer stem cells by tracing specific marker genes.

IRB Barcelona scientist Eduard Batlle wins the 2016 Carmen and Severo Ochoa Prize

He is awarded this prize for his work on colon cancer

This prestigious prize is given in recognition of molecular biology research performed by scientists working in Spain

The AECC supports cancer research at IRB Barcelona

Today the Asociación Española Contra el Cáncer (Spanish Association against Cancer) presents its 2016 Research Awards in Barcelona.

Two research projects on colon cancer will receive funding over five years.

To date, IRB Barcelona has received AECC funding for eight studies.